Diabetes

Educational resources

Leeds webinar index image 3x2

Managing patients with type 2 diabetes—a cardiometabolic pathway for a cardiovascular risk reduction approach

Promotional material from the Boehringer Ingelheim and Lilly Diabetes Alliance

This webinar has been commissioned and funded by the Boehringer Ingelheim and Lilly Diabetes Alliance and developed in partnership with Guidelines in Practice. Products are discussed.
View Jardiance®(empagliflozin) prescribing and adverse event reporting information
PC-GB-103199 March 2021

Final version - GiP supplement (print version)

Dipeptidyl peptidase-4 inhibitors—still a major player in type 2 diabetes care

Commissioned by Boehringer Ingelheim Limited

This promotional supplement has been commissioned and funded by Boehringer Ingelheim Ltd and developed in partnership with Guidelines in Practice.
View Trajenta® (linagliptin) prescribing and adverse event reporting information
PC-GB-103451 Date of preparation: January 2021

20210315 Carl Deaney

Real-world evidence in the management of type 2 diabetes: switching from other DPP‑4 inhibitors to alogliptin (Vipidia®)

Commissioned by Takeda UK Ltd

Information intended for UK healthcare professionals only. This promotional educational webinar has been organised and funded by Takeda UK Ltd.
View prescribing information and adverse event reporting information.
C-APROM/UK/VIP/0301
Date of preparation: March 2021

20210209 Takeda supplement V1 front cover image

Switching appropriate patients with type 2 diabetes to alogliptin from existing DPP-4 inhibitors: experience and outcomes from three Clinical Commissioning Groups and Local Health Boards

Commissioned by Takeda UK Ltd

Information intended for UK healthcare professionals only. This supplement has been commissioned and funded by Takeda UK Ltd. It has been developed in partnership with Grey Bear Consultancy and published by Guidelines in Practice.
View prescribing information
C-APROM/UK/VIP/0326
Date of preparation: February 2021

Takeda logo

Case study on Type 2 diabetes management: implementation of a DPP-4 inhibitor switch strategy across a primary care network

This advertorial has been commissioned and developed by Takeda UK Ltd. Information intended for UK healthcare professionals only.
View prescribing information.
C-APROM/UK/VIP/0298
Date of preparation: February 2021